Just specu_老虎社区_美港股上老虎

449ff09a
2021-11-03

Just speculation or something good behind?

Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics股价早盘飙升逾10%</blockquote>

Bionano Genomics shares surged more than 10% in morning trading. Personalized medicine is the holy

Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics股价早盘飙升逾10%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":841187246,"tweetId":"841187246","gmtCreate":1635896433111,"gmtModify":1635903754577,"author":{"id":3569133365230412,"idStr":"3569133365230412","authorId":3569133365230412,"authorIdStr":"3569133365230412","name":"449ff09a","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Just speculation or something&nbsp;good behind?</p></body></html>","htmlText":"<html><head></head><body><p>Just speculation or something&nbsp;good behind?</p></body></html>","text":"Just speculation or something good behind?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/841187246","repostId":1163085565,"repostType":2,"repost":{"id":"1163085565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635862319,"share":"https://www.laohu8.com/m/news/1163085565?lang=zh_CN&edition=full","pubTime":"2021-11-02 22:11","market":"us","language":"en","title":"Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics股价早盘飙升逾10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163085565","media":"Tiger Newspress","summary":"Bionano Genomics shares surged more than 10% in morning trading.\n\nPersonalized medicine is the holy ","content":"<p>Bionano Genomics shares surged more than 10% in morning trading.</p><p><blockquote>Bionano Genomics股价早盘飙升逾10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/341f797630babaf15e0ae9aa0dbd5c7d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.</p><p><blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现在癌症治疗中取得了许多突破，但该领域的临床成功通常以低至30%的应答率为特征。研究人员认为，这些极低的应答率源于特定患者群体内核酸和全染色体水平突变类型的差异。实际上，癌症不是一种单一的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote></p><p> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.</p><p><blockquote>因此，为了提高这些新型抗癌治疗的疗效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像Bionano Genomics这样的公司发挥作用的地方。Bionano GenomicsSport一种基于非测序的光学作图技术，称为Saphyr系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote></p><p> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.</p><p><blockquote>此外，该生物技术公司最近收购了领先的基因组学数据分析软件公司BioDiscovery。对于公司及其股东来说，这一具有里程碑意义的收购可能会成为改变游戏规则的业务发展举措。简而言之，BioDiscovery用于变异分析的NXClinical软件解决方案与Saphyr系统相结合，有可能加速光学基因组图谱的广泛采用。此外，这个潜在的同类最佳平台最终可能会在未来几年内占据这个数十亿美元市场的很大一部分。</blockquote></p><p> Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.</p><p><blockquote>Bionano定于11月4日公布第三季度收益。虽然该生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano遭受重创的股票在经历了八个月的低迷之后可能终于开始显示出一些复苏的迹象。该生物技术公司的股价目前较52周高点下跌了67%，这凸显了这一点。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics股价早盘飙升逾10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics shares surged more than 10% in morning trading<blockquote>Bionano Genomics股价早盘飙升逾10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-02 22:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Bionano Genomics shares surged more than 10% in morning trading.</p><p><blockquote>Bionano Genomics股价早盘飙升逾10%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/341f797630babaf15e0ae9aa0dbd5c7d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Personalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.</p><p><blockquote>个性化医疗是生物技术研究的圣杯。尽管随着免疫疗法的出现在癌症治疗中取得了许多突破，但该领域的临床成功通常以低至30%的应答率为特征。研究人员认为，这些极低的应答率源于特定患者群体内核酸和全染色体水平突变类型的差异。实际上，癌症不是一种单一的疾病，因此不可能开发出一种放之四海而皆准的疗法。</blockquote></p><p> To boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.</p><p><blockquote>因此，为了提高这些新型抗癌治疗的疗效，研究人员需要在个体水平上准确了解恶性肿瘤的遗传结构。这就是像Bionano Genomics这样的公司发挥作用的地方。Bionano GenomicsSport一种基于非测序的光学作图技术，称为Saphyr系统。Saphyr系统旨在快速表征极长的基因组DNA链。</blockquote></p><p> What's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.</p><p><blockquote>此外，该生物技术公司最近收购了领先的基因组学数据分析软件公司BioDiscovery。对于公司及其股东来说，这一具有里程碑意义的收购可能会成为改变游戏规则的业务发展举措。简而言之，BioDiscovery用于变异分析的NXClinical软件解决方案与Saphyr系统相结合，有可能加速光学基因组图谱的广泛采用。此外，这个潜在的同类最佳平台最终可能会在未来几年内占据这个数十亿美元市场的很大一部分。</blockquote></p><p> Bionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.</p><p><blockquote>Bionano定于11月4日公布第三季度收益。虽然该生物技术公司第三季度的收入数据不太可能引人注目，但投资者应该更多地了解这一关键收购的长期影响。因此，Bionano遭受重创的股票在经历了八个月的低迷之后可能终于开始显示出一些复苏的迹象。该生物技术公司的股价目前较52周高点下跌了67%，这凸显了这一点。反过来，激进的投资者可能希望在即将发布的收益报告之前买入一些股票。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163085565","content_text":"Bionano Genomics shares surged more than 10% in morning trading.\n\nPersonalized medicine is the holy grail of biotech research. Despite numerous breakthroughs in the treatment of cancer with the advent of immunotherapy, a clinical success in this field is generally characterized by response rates as low as 30%. Researchers believe that these exceedingly low response rates stem from differences in the mutation type at both the nucleic acid and whole chromosomal level within a particular patient population. Cancer, in effect, is not a monolithic disease, making it impossible to develop a one-size-fits-all type of therapy.\nTo boost the efficacy of these novel anti-cancer treatments, researchers thus require an accurate picture of the malignancy's genetic architecture at the individual level. That's where a company like Bionano Genomics comes into play. Bionano Genomicssportsa non-sequencing-based optical mapping technology known as the Saphyr System. The Saphyr System is designed to rapidly characterize extremely long strands of genomic DNA.\nWhat's more, the biotech recently acquired the leading genomics data analysis software company BioDiscovery. This landmark acquisition could turn out to be a game-changing business development move for the company and its shareholders. In brief, BioDiscovery's NXClinical software solution for variant analysis, combined with the Saphyr System, has the potential to accelerate the adoption of optical genome mapping at large. Moreover, this potentially best-in-class platform might ultimately grab an outsize portion of this multi-billion dollar market within the next few years.\nBionano is slated to report third-quarter earnings on Nov. 4. While the biotech's Q3 revenue figure is unlikely to turn heads, investors should learn more about the long-term implications of this key acquisition. As a result, Bionano's beaten-down stock might finally start to show some signs of life after an eight-month downturn. Underscoring this point, the biotech's shares are currently down by a whopping 67% relative to their 52-week highs. Aggressive investors, in turn, may want to pick up some shares ahead of this upcoming earnings report.","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":2619,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":37,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}